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It is now well established that the effector T cell (Teff) response is regulated by a series
of metabolic switches. Quiescent T cells predominantly require adenosine triphosphate-
generating processes, whereas proliferating Teff require high metabolic flux through
growth-promoting pathways, such as glycolysis. Pathways that control metabolism and
immune cell function are intimately linked, and changes in cell metabolism at both the
cell and system levels have been shown to enhance or suppress specific T cell effector
functions. Furthermore, functionally distinct T cell subsets require distinct energetic and
biosynthetic pathways to support their specific functional needs. In particular, naturally
occurring regulatory T cells (Treg) are characterized by a unique metabolic signature dis-
tinct to that of conventional Teff cells. We here briefly review the signaling pathways that
control Treg metabolism and how this metabolic phenotype integrates their differentiation
and function. Ultimately, these metabolic features may provide new opportunities for the
therapeutic modulation of unwanted immune responses.
Keywords: metabolism, regulatoryT cells,T cell differentiation,T cell function, mTOR pathway
METABOLIC FEATURES OF REGULATORY T CELLS
T cell differentiation and fate are orchestrated by signaling
events involving the T cell receptor (TCR), co-stimulatory or
co-inhibitory receptor stimulation, and cytokines. In addition,
a variety of other environmental factors can also contribute to
this decision. T cells switch between highly proliferative states
(i.e., developing thymocytes and activated proliferating T cells)
and quiescent states (i.e., naive, memory, and anergic T cells),
characterized by the activation of different intracellular metabolic
pathways (1). T cells use glucose as their primary fuel source for
generation of adenosine triphosphate (ATP) and it is necessary
for cell survival, growth, activation, proliferation, and cytokine
production (2, 3).
T cell receptor stimulation is accompanied by signals from
growth factors and cytokines such as interleukin (IL)-2 or IL-
7, and co-stimulatory molecules, such as CD28, which lead to
an increase in glucose uptake and glycolysis through induction
of phosphoinositide-3-kinase (PI3K)-dependent activation of Akt
(4). Akt induces glucose metabolism by facilitating glucose uptake
via the upregulation of glucose transporter 1 (Glut1) on the T cell
membrane (5). Failure of T cells to up-regulate glucose metabo-
lism results in decreased cytokine production, proliferation, and
ultimately to apoptosis (6–8) or anergy (9). An increase in the rate
of protein synthesis also occurs following T cell activation and is
regulated via Akt, which controls the activation of the mammalian
target of rapamycin (mTOR), which is a key regulator of protein
synthesis in T cells (10, 11).
Naturally occurring regulatory T cells (Treg), defined as
CD4+CD25+Foxp3+ T cells, play a non-redundant role in the
maintenance of physiological tolerance to self-antigens and pre-
vention of autoimmune responses (12, 13). Treg generation in
the thymus is promoted by recognition of self-peptides with
intermediate affinity (14). Treg cells are characterized by a specific
metabolic signature regulating their responsiveness to antigenic
stimulations when compared to other CD4+ T cell subsets (15–
18). Specifically, Th1, Th2, and Th17 cells express high surface
levels of Glut1 and are highly glycolytic. Treg, in contrast, express
low levels of Glut1 and have high lipid oxidation rates in vitro
(19). Furthermore, blocking glycolysis promotes Treg cell gener-
ation through the transcription factor hypoxia-inducible factor
1α (HIF1α), whose induction required mTOR pathway activation
(20). In turn, HIF1α enhances Th17 development through direct
transcriptional activation of RORγt, and concurrently, it atten-
uates Treg development, by binding FoxP3 and targeting it for
proteasomal degradation.
Collectively, these observations underscore the key role of meta-
bolic cues and regulatory pathways in defining T cell differentia-
tion and function (Figure 1).
mTOR INHIBITION AND Treg DIFFERENTIATION
The mTOR is a key regulator of T cell metabolism, that serves
to integrate nutrient sensing pathways with signaling pathways
involved in differentiation, growth, survival, and proliferation
(21). TCR and co-stimulatory signals along with cytokines tweak
the mTOR pathway via the upstream PI3K/Akt signaling networks
to match the energy requirements associated with T cell activation
(22, 23). Conventional CD4+ and CD8+ T cells, upon stimula-
tion, utilize the mTOR pathway to meet the increased metabolic
demands of T cell activation by switching from primarily oxida-
tive phosphorylation, seen in resting T cells, toward a state of
enhanced aerobic glycolysis, a phenomenon popularly described
as the Warburg effect (3, 24, 25). The importance of this phenom-
enon in determining T cell fate was first noticed using the selective
inhibitor of mTOR, rapamycin, which prevented the generation
www.frontiersin.org November 2014 | Volume 5 | Article 590 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coe et al. Metabolic regulation of Treg
FIGURE 1 | mTORC1 is a key regulator ofTreg andTeff activation and
differentiation. Signaling through the TCR is accompanied by cytokine
signals from IL-2, IL-7, and leptin as well as co-stimulation via CD28.
Together, these signals cause increased glycolysis through the induction of
PI3K-dependent activation of Akt, which in turn increases glucose transport
via the upregulation of Glut1 on the T cell surface. Activated pAkt increases
the rate of protein synthesis via activation of mTORC1. Activated mTORC1
activates HIF1α, regulates lipid metabolism and glycolysis.
of Teff responses and promoted the generation of Treg cells (9, 26–
28). Additionally, T cell-specific mTOR knockouts were shown to
have poor Teff responses and defaulted toward a more Treg phe-
notype (29). These studies not only revealed the importance of
mTOR as a critical regulator in the differentiation of Treg, but
also highlighted the importance of the metabolic pathways that
predominate within functionally different T cell subsets.
Consistent with the above findings, Treg display higher levels
of AMP kinase activity and preferential lipid oxidation for their
energy requirements (19). The AMP-activated kinase acts as a sen-
sor of the AMP/ATP ratio, which is increased during hypoxia and
inhibits mTOR kinase to promote mitochondrial oxidative metab-
olism rather than glycolysis (30, 31). Interestingly, activation of
AMP kinase via Metformin, a drug used to treat diabetes mellitus,
increased the Treg population in the CD4+ T cell compartment in
an in vivo murine model of asthma (19). In this study, mice sensi-
tized by aerosol to ovalbumin in the presence of metformin, and
challenged 21 days later showed an increase in the frequency and
number of CD4+Foxp3+ T cells in the draining lymph nodes as
compared to mice immunized in the absence of metformin. How-
ever, no change in airway responsiveness was noted even though
there were fewer lymphocytes recovered in the bronchial alveolar
lavage in the metformin treated animals. Additionally, inhibi-
tion of mitochondrial lipid uptake and oxidation pathways by
Etomoxir, an inhibitor that prevents long chain fatty acid uptake to
the inner mitochondrial membrane for beta oxidation, abrogated
the generation of Treg without altering Teff differentiation (19).
Furthermore, Treg were shown to express lower levels of the glu-
cose transporter Glut1 as compared to Teff , and transgenic CD4
+ T
cells overexpressing Glut1 were shown to develop fewer Treg. Over-
all, these studies indicate that fatty acid oxidation is the dominant
metabolic process utilized for the generation of energy in Treg.
mTOR AND Treg FUNCTION
While inhibition of mTOR enhances Treg generation during an
immune response, mTOR activity is known to be required to
maintain their suppressive capabilities. In this section, we review
recent findings that investigated this apparent dichotomy in the
function of mTOR in Treg biology. mTOR exists as two struc-
turally distinct complexes (mTORC1 and mTORC2). Both com-
plexes localize within different subcellular compartments and
have different functions in the cell; rapamycin-sensitive mTORC1
forms the fundamental nutrient sensing complex that is acti-
vated by Akt kinase downstream of PI3K signaling induction (via
the TCR, co-stimulatory receptors, and cytokines) whereas the
rapamycin-insensitive mTORC2 controls spatial aspects of cell
growth through activation of cytoskeletal components (32, 33).
The mTORC2 complex also, in turn, activates the kinase Akt (34,
35). Thus, Akt lies both upstream and downstream of mTOR. In
mice, CD4+ T cells lacking both mTORC1 and mTORC2 com-
plexes fail to differentiate into any Teff lineage (Th1, Th2, or Th17)
and instead differentiate toward the Treg cell phenotype, consistent
with the CD4+ population of mTOR null mice (36). However,
recent findings by Hu Zheng et al. indicate a crucial role of the
mTORC1 complex to the suppressive activity of Treg (29). Indeed,
mTORC1 activity was shown to be higher in Treg than naive T cells
under steady state conditions. Impairment of the mTORC1 path-
way in Treg via selective genetic deletion of Raptor, an obligatory
component of mTORC1, in the CD4+ FOXP3+ compartment, led
to the early onset of a fatal autoimmune disease in mice (29). More-
over, the disease mimicked the autoimmune disease seen in Scurfy
mice that bear a loss-of-function mutation in the FoxP3 transcrip-
tion factor, indicating impaired Treg function. Mechanistically, the
mTORC1 pathway in Treg was shown to be necessary to initiate the
upregulation of surface CTLA-4 and ICOS, key intrinsic receptors
for Treg-mediated suppression. In addition, mTORC1 was shown
to induce cholesterol and lipid metabolism as well as prolifer-
ation in the Treg population (29). Finally, recent investigations
have revealed a non-redundant role of mTORC1 in mitochon-
drial metabolism (37). Collectively, these investigations imply a
differential use of mTOR in Treg as compared to conventional
effector cells.
A MODEL OF Treg DIFFERENTIATION BASED ON mTOR
ACTIVATION
From the aforementioned studies, it is clear that the metabolic cues
from the environment and subsequent mTOR activity play a key
role in Treg differentiation. Powell et al. have proposed a model of
Treg differentiation based on mTOR activity that mimics that seen
in conventional T cell differentiation. Briefly, naïve T cells, receiv-
ing strong mTOR activation upon antigen recognition (through
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environmental cues, TCR, cytokine, and co-stimulatory stimu-
lation), differentiated into short-lived Teff cells exhibiting high
glycolytic activity, while those receiving weak mTOR activation
developed into long-lived memory T cells dependent on oxidative
phosphorylation to meet their energy needs (38). One can suggest
that the high level of mTOR activity in Teff cells would be necessary
to sustain higher demand for energy via glycolytic pathways while
the opposite would hold true for quiescent memory T cells. A sim-
ilar model can be applied to induced Treg where naïve T cells in the
presence of TGF-β receiving either high or low mTOR activating
signals could result in the differentiation of “effector” and “mem-
ory” Foxp3+ Treg respectively. As such, CD4+ Foxp3+ T cells that
traffic to activating lymph nodes and become robustly stimulated
(mTORhi) generate short-lived “effector” Treg. These effector Treg
would then home to the tissues and control immune responses.
This model can explain why T cells stimulated in vitro with high
doses of peptide in the presence of exogenous TGF-β develop into
Treg. These mTORhi Treg exhibit high glycolytic activity similar
to that of conventional Teff cells (Figure 2). Consequently, this
model can also be applied to natural Treg cells differentiation into
effector or memory Treg arising through associated mTOR hi or
low activity upon antigen recognition (38).
OSCILLATING mTOR ACTIVITY PROMOTES PROLIFERATION
IN Treg
A hallmark feature of Treg cells is their ability to proliferate abun-
dantly in vivo while remaining anergic and poorly proliferative
in vitro (39, 40). This anergic in vitro state was shown to be
reversible via activation in the presence of supra-physiologic con-
centrations of IL-2 (41). In addition, short-term treatment of Treg
with rapamycin preceding activation in the presence of supra-
physiologic quantities of IL-2 was shown to promote proliferation
FIGURE 2 |The level of mTORC1 activity and glycolysis is important for
differentiation ofT cell subsets. mTORC1 integrates nutrient sensing and
signaling pathways to match the energy requirements of activated T cells.
Th1, Th2, and Th17 cells require high levels of glycolysis that is mediated by
high mTORC1 activity, whereas Treg differentiation requires variable mTorc
activity, reduced glycolysis, and lipid oxidation.
in vitro at much higher levels than those induced by IL-2 alone.
This posed a conundrum as to how two signals having opposite
effects on mTOR activity can converge to enhance proliferation of
Treg. To explain this phenomenon, a model was put forward (18),
which postulates that mTOR activity in Treg is highly dynamic,
oscillating between low and high activation states. As mentioned
before, mTOR activity in Treg was shown to be higher at rest-
ing states when compared to naïve Teff . According to this model,
the intermittent reduction in mTOR signaling followed by its
enhanced activation by means of TCR triggering and IL-2 stimu-
lation promotes Treg proliferation. However, Treg requirement for
down-regulation of mTOR signaling was shown to be short-lived
as protracted incubation with rapamycin ablated their prolifera-
tion. This model also identified the adipocyte hormone leptin as
a key signal that regulates mTOR activity in vivo, promoting Treg
proliferation. Within the immune system, leptin has been seen to
activate pro-inflammatory cells while diminished leptin levels can
lead to immunosuppression (42). Leptin produced by Treg cells
was shown to contribute to the activation of the mTOR path-
way in an autocrine manner. Other mechanisms through which
mTOR activity is maintained in its oscillating state to overcome
their hypo-responsiveness and enter the cell cycle continue to be
investigated.
METABOLIC REGULATION OF Treg AND Th17
DIFFERENTIATION
Interleukin-17 (Th17) producing and induced regulatory T cells
(iTreg) differentiate from naïve CD4+ T cells and mediate diverse
and often opposing effects in lymphoid and peripheral tissues.
Under the influence of TGFβ and IL-2, naive T cells are induced
to express the transcription factor FoxP3, and differentiate into
tissue-resident iTreg, which support a suppressive environment.
However, in the presence of IL-6, naive T cells stimulated with
TGFβ express the transcription factors STAT3 and Rorγt, secrete
IL-17, and produce an inflammatory environment.
It has recently emerged that metabolic factors can modulate
the balance of Th17 and iTreg cells resulting in inflammation or
actively maintained tolerance.
Commitment to the Th17 lineage, like other Teff , requires
increased mTORC1 activity to sustain differentiation and func-
tion. As the presence of TGFβ is required for the development of
both Th17 and Treg cell subsets, the relative differentiation of each
cell type can be influenced by the level of mTORC1 activation. This
interconnectivity is especially significant because of the opposing
functions of the two cells types. The metabolic regulation and
influence on the Th17:Treg ratio has been articulately reviewed by
Barbi, Pardoll, and Fan-Pan (43) and so is briefly summarized here.
The activation of mTOR, and the subsequent switch to aero-
bic glycolysis, is essential for Th17 development; IL-1 enhances
Th17 cell differentiation and proliferation via mTOR activation
(44) whereas mTOR inhibition prevents Th17 differentiation (45,
46) and ameliorates Th17-dependent symptoms in a murine EAE
model (47). Concomitantly, in these experiments, mTOR inacti-
vation increases Treg cell numbers and function and sensitizes Treg
to TGFβ (45, 48).
As well as mTOR, hypoxia-inducible factor (HIF1α), a tran-
scription factor activated during inflammation and in response to
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low oxygen levels, is a critical regulator of metabolism. In T cells,
HIF1α plays a role in inducing aerobic glycolysis even in the pres-
ence of plentiful oxygen (49). Elevated glycolysis in Th17 cells is
dependent on HIF1α, and indeed, the transcription factor is essen-
tial for their differentiation and function (20). HIF1α activation,
under aerobic conditions, is modulated by mTORC1 and there-
fore the concerted actions of HIF1α and mTORC1 preferentially
guide Th17 cell development and effector functions. Furthermore,
HIF1α directly binds to FoxP3 and targets it for proteosomal
degradation while also increasing the transcription of the Th17-
related transcription factor Rorγt. Mice with HIF1α-deficient T
cells are resistant to Th17-dependent EAE with a response that is
characterized by a decrease in Th17 cells and an increase in Treg
cells (50). Thus, HIF1α and mTOR represent important mediators
of the Th17:Treg balance in hypoxic and inflamed tissues, and as
such are potentially important targets for clinical interventions.
VISCERAL ADIPOSE TISSUE-ASSOCIATED Treg
Metabolic stress is also known to influence the development of
Treg, and specifically to affect adipose-tissue-resident Treg cells.
This population of Treg produces high levels of IL-10 and is char-
acterized by the expression of GATA3, CCR2, KLRG1, and lack
of CD103 expression (51). Visceral adipose tissue (VAT) Treg are
thought to be important for the maintenance of responsiveness
to insulin, by regulating adipokine release. In obese humans and
mice, VAT Treg are progressively replaced by a pro-inflammatory
Teff cell infiltrate, which accumulates in adipose tissue and pro-
duces cytokines that causes systemic low grade chronic inflam-
mation (52–54), subsequently leading to insulin resistance and
other obesity-related morbidities. VAT resident Treg negatively
regulate inflammation and represent a tissue specific Treg pop-
ulation that express a distinct T cell repertoire (52) and a unique
transcription factor, peroxisome-proliferator-activated receptor γ
(PPARγ) (51). Obesity in mice and humans causes a reduction
in VAT-associated Treg differentiation (55). Moreover, removal
of VAT resident Treg by conditional knock-out of PPARγ, or
activation, by treatment with pioglitazone, modulates levels of
inflammatory cell subsets and insulin sensitivity (51). Leptin, a
class I cytokine, is produced in higher amounts by adipocytes
in obese individuals and inhibits rapamycin-induced prolifera-
tion of Treg via increased activation of mTORC1 (18, 56). Leptin,
secreted in the VAT, therefore, represents a potential regulator of
the function of adipose-tissue-resident Treg. In contrast to lep-
tin, adiponectin, an anti-inflammatory adipokine, retains insulin-
sensitizing properties and negatively correlates with body mass
index while positively correlating with Treg cell representation in
VAT (57).
AMINO ACID CONCENTRATION REGULATES Treg
DIFFERENTIATION AND FUNCTION
Regulatory T cell differentiation and function are also controlled
by the availability of amino acids in the local milieu. The essen-
tial amino acids arginine, glutamine, and tryptophan are essential
for T cell activation (58–61) and their depletion from the local
microenvironment results in Treg generation. For example, Tryp-
tophan is catabolized by indoleamine 2,3-dioxygenase (IDO) and
tryptophan 2,3-dioxygenase (TDO), which are present on many
suppressive cell types including regulatory dendritic cells (DC)
and some tumors. Low concentrations of tryptophan inhibits
T cell growth but enhances Treg generation (62–64) through an
mTOR-dependent mechanism (65). The depletion of arginine by
arginase (ARG1) and nitric oxide synthase (iNOS) also inhibits
T cell activation via mTor inhibition. ARG1, iNOS, and IDO can
be induced by Treg in actively tolerant skin grafts in vivo (66)
providing a feed-back loop by which Treg can influence amino
acid availability via autocrine mTOR activation and subsequently
control Teff activation and function. The influence of amino acid
metabolism on Treg differentiation and function has been reviewed
elsewhere (67).
THERAPEUTIC IMPLICATIONS
The metabolic pathways influencing Treg differentiation and func-
tion are amenable for modulation in therapeutic settings, thus
providing the clinician with potentially valuable tools in the fight
against immune-mediated diseases. As the mechanisms by which
Rapamycin affects Treg function are elucidated, more areas of
clinical intervention will be opened for this FDA approved, well
tolerated, and bio-available drug. To this end, it has recently been
demonstrated by Makki et al. (68) that the metabolic effects of
Rapamycin can protect against insulin resistance, increase energy
expenditure, and reduce weight gain in diet-dependent obese mice.
These phenotypic effects correlate with an increase of Treg and
myeloid derived suppressor cells in the adipose tissue (68). These
finding will certainly fuel the debate over the use of Rapamycin
beyond organ transplantation.
Proglisterone, which is currently licensed as a drug for the
treatment of Type II diabetes, provides another potential target
to modulate Treg metabolism. Proglisterone is known to stim-
ulate PPARγ and when used to treat mice fed a high fat diet,
it restores the number and function of visceral adipose specific
Treg and this effect appears to be PPARγ specific (51). Therefore,
Proglisterone can potentially target pathologies related to VAT Treg
with no bystander effects on other Treg populations. The regula-
tion of accumulation and function of PPARγ+ Treg by leptin and
adiponectin represents a potentially valuable therapeutic pathway
that may, in the future, be targeted in order to regulate obesity-
related pathologies. Moreover, the role of leptin and Treg in the
progression of obesity-related diabetes is yet to be fully elucidated
and may provide even more targets for future drug research.
On another note, and potentially related to Treg dependence
on fatty acid metabolism, short-chain fatty acids (scFA), of bac-
terial origin (i.e., propionate, butyrate, and acetate), can restore
the Treg compartment in the gut of germ-free mice that had been
treated with irradiation or antibiotics. This re-population is par-
tially dependent on the expression of free fatty acid receptor 2
(FFAR2) on colonic Treg, which physiologically express higher
levels of FFAR2 than other Treg sub-populations. This observation
opens up the tantalizing possibility that colonic Treg may be specif-
ically targeted, in clinical settings, using synthetic scFA to treat
gut-related problems in immunocompromised individuals (69).
CONCLUDING REMARKS AND PERSPECTIVES
The recent ground breaking research in how metabolism effects
Treg biology has provided the scientific and medical community
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with a plethora of novel mechanistic insights that will inevitably
lead to a better understanding of disease and a host of therapeu-
tic targets. However, we still need to understand how the varying
tissue-specific transcription factors found in Treg sub-populations
are influenced by their environment, external and internal meta-
bolic factors. The expression of PPAR-γ by VAT Treg suggests that
the metabolic environment can influence the expression of tran-
scription factors not only in resident cells but also in new migrants
to the tissue. A future challenge will involve extending this concept
to establish whether the metabolic microenvironment,which char-
acterizes different tissues, can determine the balance of regulation
versus inflammation in situ. If true, this possibility will pave the
way for organ-selective immune-metabolic therapy.
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